Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Busulfan vs TBI Conditioning for Adult ALL in CR2
NCT07919470Phase 3Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Nov 2026
- Primary completion
- Nov 2028
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of busulfan in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Peking University People's Hospital. Primary endpoint: Leukemia-Free Survival at 12 months. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
busulfan
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT07919470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07919470.